This Collection invites original research articles on phase contrast imaging, looking at the latest technological developments and the use of this technique in original applications. Phase contrast ...
GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.
GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Figure 1： The flowchart of ACDPC iterative reconstruction joint optimization algorithm. (a) ACDPC imaging system based on half-annular illumination. (b) Three annular illumination patterns and their ...
Techniques that exploit the phase of X-rays, not just their absorption, have the potential to transform X-ray imaging in hospitals, reports Jude Dineley Improved imaging Marian Willner from the ...
Zacks Investment Research on MSN
GEHC moves manganese-based MRI contrast agent into phase 2/3 trial
GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...
Researchers all over Germany have developed a new system for X-ray imaging, which is suited for both living specimens and sensitive materials. The system records images of micrometer resolution at a ...
Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results